PCRX Q3 2019 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$105M+25.4% YoY

Gross Profit

$82M78.7% margin

Operating Income

$2M2.3% margin

Net Income

-$6M-5.8% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+2.0%

Cash Flow

Operating Cash Flow

$18M

Free Cash Flow

$17M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$807M

Total Liabilities

$461M

Stockholders' Equity

$346M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$105M	$83M	+25.4%
Gross Profit	$82M	$64M	+28.0%
Operating Income	$2M	$4M	-40.4%
Net Income	-$6M	-$640,000	-851.1%

Revenue Segments

Product

$104M100%

Royalty

$335,0000%